All eukaryotic cells can secrete extracellular vesicles, which have a double-membrane structure and are important players in the intercellular communication involved in a variety of important biological processes. Platelets form platelet-derived microparticles (PMPs) in response to activation, injury, or apoptosis. This review introduces the origin, pathway, and biological functions of PMPs and their importance in physiological and pathological processes. In addition, we review the potential applications of PMPs in cancer, vascular homeostasis, thrombosis, inflammation, neural regeneration, biomarkers, and drug carriers to achieve targeted drug delivery. In addition, we comprehensively report on the origin, biological functions, and applications of PMPs. The clinical transformation, high heterogeneity, future development direction, and limitations of the current research on PMPs are also discussed in depth. Evidence has revealed that PMPs play an important role in cell-cell communication, providing clues for the development of PMPs as carriers for relevant cell-targeted drugs. The development history and prospects of PMPs and their cargos are explored in this guidebook.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11016590 | PMC |
| http://dx.doi.org/10.1016/j.ajps.2024.100907 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Potential Clinical Relevance of Procoagulant Microparticles as Biomarkers of Blood Coagulation in Breast Cancer: A Systematic Review.
Asian Pac J Cancer Prev
January 2025
Research Center for Noncommunicable Disease, Jahrom University of Medical Sciences, Jahrom, Iran.
Background: Breast cancer (BC) is a global challenge that affects a large portion of individuals, especially women. It has been suggested that microparticles (MPs) can be used as a diagnostic, prognostic, or therapeutic biomarker in various diseases. Moreover, MPs are known to elevate in cancer cases.
View Article and Find Full Text PDFComplex Pattern of Platelet Activation/Reactivity After SARS-CoV-2 Infection.
Int J Mol Sci
December 2024
Department of Hemostasis and Hemostatic Disorders, Medical University of Lodz, Mazowiecka 6/8, 92-215 Lodz, Poland.
COVID-19 and post-COVID (long COVID) are associated with thromboembolic complications; however, it is still not clear whether platelets play a leading role in this phenomenon. The platelet hyperreactivity could result from the direct interaction between platelets and viral elements or the response to inflammatory and prothrombotic factors released from blood and vessel cells following infection. The existing literature does not provide clear-cut answers, as the results determining platelet status vary according to methodology.
View Article and Find Full Text PDFEngineered platelets as targeted protein degraders and application to breast cancer models.
Nat Biotechnol
December 2024
Pharmaceutical Sciences Division, School of Pharmacy, University of Wisconsin-Madison, Madison, WI, USA.
Clinical application of chimeric molecules for targeted protein degradation has been limited by unfavorable drug-like properties and biosafety concerns arising from nonspecific biodistribution after systemic administration. Here we develop a method to engineer platelets for degradation of either intracellular or extracellular proteins of interest (POIs) in vivo by covalently labeling heat shock protein 90 (HSP90) in platelets with a POI ligand. The degrader platelets (DePLTs) target wound areas and undergo activation.
View Article and Find Full Text PDFRisk of Atherosclerosis Due to HMGB1-dependent Platelet-derived Microparticles in Patients with Type 2 Diabetes Mellitus.
Clin Appl Thromb Hemost
November 2024
First Department of Internal Medicine, Kansai Medical University, Hirakata, Japan.
We measured high mobility group box 1 protein (HMGB1) and platelet-derived microparticles (PDMP) in blood samples from patients with untreated type 2 diabetes mellitus (T2DM). We examined the effects of a combination of sodium/glucose cotransporter 2 (SGLT2) inhibitors and dipeptidyl peptidase-4 (DPP-4) inhibitors. Multiple regression analysis of HMGB1 was conducted on data from 252 patients in our previously reported T2DM-related clinical study.
View Article and Find Full Text PDFA study of platelet function in patients with chronic immune thrombocytopenia treated with thrombopoietin receptor agonists.
Thromb Res
December 2024
Hematology Unit, First Department of Internal Medicine, Laikon General Hospital, National & Kapodistrian University of Athens, Athens, Greece.
Background: Thrombopoietin receptor agonists (TPO-RAs) are widely used in immune thrombocytopenia (ITP) and are associated with increased thrombotic risk. However, data regarding their impact on platelet function is scarce.
Methods: Platelet function was evaluated in chronic ITP patients enrolled over one year, using light transmission aggregometry and platelet-derived microparticle (PMP) levels measurement with flow cytometry.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!